Shankar Thangamani, DVM, PhD

Assistant Professor


Midwestern University
College of Veterinary Medicine
Department of Pathology and Population Medicine
Cactus Wren 336-N
19555 N. 59th Ave. Glendale, AZ 85308

Office: (623) 537-6378
e-mail:sthang@midwestern.edu



EDUCATION

PhD Microbiology Purdue University 2016
DVM Veterinary Medicine Madras Veterinary College, India 2009

RESEARCH SUMMARY

i) Therapeutics for Bacterial and Fungal infections. Opportunistic pathogens in the gastrointestinal (GI) tract including Candida albicans, Clostridium difficile, Clostridium perfringens and Enterococcus causes life-threatening infections in humans and animals.  However, a limited number of approved antimicrobial drugs in addition to the emergence of strains resistant to current antibiotics and antifungal agents suggest an alternative, novel methods to prevent and treat these infections are in urgent need. Since the majority of enteric bacterial and fungal infections stem from endogenous GI colonization, understanding the mechanisms associated with GI colonization is essential to develop novel approaches to prevent colonization and pathogenesis.

My laboratory is primarily interested in understanding the role of gut metabolites and microbiota in the GI colonization of enteric pathogens. Utilizing metabolomics, sequencing, in vitro and in vivo mouse models, and clinical samples from humans and animals, understanding role of gut microbiota and metabolites in the GI colonization of C. albicans, C. difficile and C. perfringens will guide personalized medicine and improve drug discovery and development.  In collaboration with medicinal chemists, our laboratory is also interested in developing small molecule inhibitors for the treatment of bacterial and fungal diseases. 

(ii) Role of gut microbiota in the biotransformation of drugs. Recent evidences has shown that gut microbes influence the efficacy of FDA-approved drugs. Gut microbiota express enzymes that can either metabolically inactivate or activate drugs. Understanding the role of gut microbiota in drug metabolism will aid to improve the existing therapy and to develop novel drug therapies.

RECENT PUBLICATIONS

Antibiotic-induced alterations in taurocholic acid levels promote gastrointestinal colonization of Candida albicans. Guinan J and Thangamani S. FEMS Microbiology Letters, 2018.

Secondary bile acids inhibit Candida albicans growth and morphogenesis.Guinan J, Villa P and Thangamani S. Pathogens and Disease, 2018.

Complete List:  https://www.ncbi.nlm.nih.gov/pubmed/?term=shankar+thangamani